Vivesto AB (SE:VIVE)
:VIVE
Top Page
Vivesto AB
(VIVE)
Select Model
Select Model
Rating:43Neutral
Price Target:
kr0.08
▼(-2.50% Downside)
Action:N/ADate:03/01/26
The score is driven primarily by weak financial performance (ongoing losses, cash burn, and a shrinking equity base), with technicals also bearish as the price trades below all key moving averages and MACD is negative. Valuation is not supportive due to negative earnings and no indicated dividend yield.
Positive Factors
Low leverage
The company’s low debt burden provides durable financial flexibility: manageable interest and principal obligations reduce refinancing risk and preserve capacity to fund R&D or clinical programs. Over months this lowers bankruptcy risk and supports strategic options despite cash burn.
Negative Factors
Persistent net losses
Recurring multi-year losses erode capital and force reliance on external funding. Persistent negative earnings limit reinvestment, weaken investor confidence, and create ongoing pressure to secure dilutive financing or partnerships to sustain clinical and regulatory programs.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage
The company’s low debt burden provides durable financial flexibility: manageable interest and principal obligations reduce refinancing risk and preserve capacity to fund R&D or clinical programs. Over months this lowers bankruptcy risk and supports strategic options despite cash burn.
Read all positive factors
Vivesto AB (VIVE) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr85.69M
Dividend YieldN/A
Average Volume (3M)410.92K
Price to Earnings (P/E)―
Beta (1Y)-0.24
Revenue GrowthN/A
EPS GrowthN/A
CountrySE
Employees4
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.01
Shares Outstanding1,107,137,000
10 Day Avg. Volume214,919
30 Day Avg. Volume410,918
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)0.58
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.03
Revenue Forecast (FY)N/A
Vivesto AB Business Overview & Revenue Model
Company Description
Vivesto AB develops, produces, markets, and sells drugs in the field of human and veterinary oncology primarily in Sweden. Its lead product is Apealea (paclitaxel micellar) for the treatment of ovarian cancer. The company's products portfolio incl...
How the Company Makes Money
null...
Vivesto AB Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
56
Neutral
Cash Flow
22
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2022 | Dec 2021 | Apr 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 1.01M | 26.19M | 201.84M |
| Gross Profit | 0.00 | -3.19M | -10.66M | -17.93M | 215.84M |
| EBITDA | -34.38M | -36.56M | -89.76M | -97.62M | -11.50M |
| Net Income | -34.08M | -39.75M | -367.03M | -138.94M | -10.53M |
Balance Sheet | |||||
| Total Assets | 149.04M | 172.88M | 355.88M | 594.31M | 863.54M |
| Cash, Cash Equivalents and Short-Term Investments | 2.10M | 32.29M | 142.51M | 97.27M | 287.40M |
| Total Debt | 13.00M | 0.00 | 8.17M | 10.43M | 0.00 |
| Total Liabilities | 24.46M | 14.55M | 30.45M | 44.59M | 176.80M |
| Stockholders Equity | 124.58M | 158.33M | 325.42M | 549.71M | -1.22B |
Cash Flow | |||||
| Free Cash Flow | 0.00 | -47.25M | -80.79M | -179.91M | -211.41M |
| Operating Cash Flow | -33.96M | -47.25M | -80.52M | -145.56M | -204.86M |
| Investing Cash Flow | 21.85M | 43.40M | -45.28M | 118.65M | -21.55M |
| Financing Cash Flow | 13.00M | 0.00 | 128.76M | -5.81M | -6.01M |
Vivesto AB Peers Comparison
UnderperformOutperform
Sector (51)
SE:VIVE
Vivesto AB
0.08
-0.13
-62.07%
DE:AC6
AlzeCure Pharma AB
0.10
-0.08
-46.07%
DE:5J2
Gabather AB
―
―
―
DE:6FN
Klaria Pharma Holding AB
0.09
>-0.01
-5.05%
DE:40M
Nanexa AB
0.33
0.25
352.78%
SE:ERMA
Enorama Pharma AB
0.41
-2.05
-83.29%
Vivesto AB Corporate Events
Vivesto Advances Cantrixil With First Dogs Dosed in PK/Toxicology Study
Mar 13, 2026
Vivesto AB has initiated dosing of the first dogs in a pharmacokinetic and toxicology study of its cancer drug candidate Cantrixil, a key step in its hematological cancer development program. The exploratory study in four dogs will assess exposure...
Vivesto Boosts Share Count After Rights and Set-Off Issues
Feb 27, 2026
Vivesto AB, a Swedish oncology-focused development company listed on Nasdaq Stockholm, is advancing drug candidates for difficult-to-treat cancers in both human and veterinary medicine, including its blood cancer project Cantrixil and the Paccal V...
Vivesto Settles Rights Issue Guarantee Fees with Directed Share Issue to Preserve Cash
Jan 29, 2026
Vivesto AB’s board has approved a directed issue of 31,050,000 new shares to guarantors of its recently completed rights issue, using the mandate granted at an extraordinary general meeting in December 2025. The compensation shares, priced a...
Vivesto Raises SEK 53.8 Million in Fully Subscribed Rights Issue With Significant Shareholder Dilution
Jan 23, 2026
Vivesto AB has completed a fully subscribed rights issue, raising approximately SEK 53.8 million before costs at a subscription price of SEK 0.10 per share, with about 62.1 percent of the offering taken up through subscription rights, 1.9 percent ...
Vivesto Launches Fully Covered SEK 53.8 Million Rights Issue to Fund Veterinary Oncology Pipeline
Jan 2, 2026
Vivesto AB has published an information document for a fully covered rights issue of approximately SEK 53.8 million, offering existing shareholders one new share at SEK 0.10 for each share held, with trading in subscription rights on Nasdaq Stockh...
Vivesto Shareholders Approve Heavily Guaranteed Rights Issue to Bolster Cancer Drug Development
Dec 22, 2025
Vivesto AB’s extraordinary general meeting on 22 December 2025 approved a major rights issue of up to 538,043,455 new shares at SEK 0.10 per share, with preferential subscription rights for existing shareholders, requiring amendments to the ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.